Department of Vascular Surgery, Medical University of Lublin, Staszica 11 St., 20-081 Lublin, Poland.
Department of Analytical Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.
Int J Mol Sci. 2023 Aug 18;24(16):12917. doi: 10.3390/ijms241612917.
Chronic venous disease (CVD) is a condition characterized by functional disturbances in the microcirculation of the superficial and deep veins, affecting up to 30% of the global population. Diosmin, a phlebotropic drug, is commonly used in the treatment of CVD, and its beneficial effects have been described in numerous clinical studies. However, the precise molecular mechanism underlying the activity of diosmin is not yet fully understood. Therefore, the objective of our study was to investigate whether diosmin has an impact on oxygen management, as cardiovascular diseases are often associated with hypoxia. In our study, patients were administered a daily dosage of 2 × 600 mg of diosmin for 3 months, and we evaluated several factors associated with oxygen management, angiogenesis, and inflammation using biochemical assays. Our findings indicate that diosmin reduced the levels of fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF-C), while increasing endostatin and angiostatin levels, suggesting a potential influence on angiogenesis regulation. Furthermore, diosmin exhibited anti-inflammatory properties by suppressing the levels of tumor necrosis factor-alpha (TNF-α), interleukin 1-beta (IL-1β), and interleukin 6 (IL-6), while promoting the production of interleukin 12 (IL-12). Additionally, diosmin significantly decreased the levels of hypoxia-inducible factor (HIF), anion gap (AG), and lactate, indicating its potential influence on the hypoxia-inducible factor pathway. These findings suggest that diosmin may play a crucial role in modulating oxygen management and inflammation in the context of chronic venous disease.
慢性静脉疾病（CVD）是一种以浅静脉和深静脉微循环功能障碍为特征的疾病，影响全球人口的 30%。地奥司明是一种静脉活性药物，常用于 CVD 的治疗，许多临床研究已经描述了其有益作用。然而，地奥司明的活性的确切分子机制尚未完全了解。因此，我们的研究目的是探讨地奥司明是否对氧气管理有影响，因为心血管疾病通常与缺氧有关。在我们的研究中，患者每天服用 2×600mg 的地奥司明，持续 3 个月，并使用生化测定法评估与氧气管理、血管生成和炎症相关的几个因素。我们的研究结果表明，地奥司明降低了成纤维细胞生长因子（FGF）和血管内皮生长因子（VEGF-C）的水平，同时增加了内皮抑素和血管抑素的水平，表明其对血管生成调节可能有潜在影响。此外，地奥司明通过抑制肿瘤坏死因子-α（TNF-α）、白细胞介素 1-β（IL-1β）和白细胞介素 6（IL-6）的水平，促进白细胞介素 12（IL-12）的产生，具有抗炎作用。此外，地奥司明显著降低缺氧诱导因子（HIF）、阴离子间隙（AG）和乳酸的水平，表明其对缺氧诱导因子通路可能有影响。这些发现表明，地奥司明在调节慢性静脉疾病中的氧气管理和炎症中可能发挥关键作用。
